Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Polidocanol Endovenous Microfoam · 1 trial · 1 indication
Cmax measured and adjusted for weight
| Arm | Type | Description |
|---|---|---|
| High Dose Polidocanol Endovenous Microfoam | EXPERIMENTAL | - |
| Medium Dose Polidocanol Endovenous Microfoam | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Polidocanol Endovenous Microfoam (PEM) | DRUG | Pharmacokinetic comparison of different doses of drug |
Inclusion Criteria: * Male or female; age 18 to 75 years * Superficial venous disease where SFJ incompetence is the predominant source of reflux (reflux \> 0.5 seconds on duplex ultrasonography) associated with incompetence of the great saphenous vein (GSV) or other major accessory vein * Expected ...
Polidocanol Endovenous Microfoam is used for the treatment of varicose veins. It is a small molecule therapy in the cardiovascular therapeutic area, administered as an endovenous microfoam. The drug is being developed by Boston Scientific Corporation for this vascular condition.
Boston Scientific Corporation (BSX) is the developer of Polidocanol Endovenous Microfoam. The company is conducting clinical research on this investigational drug for the treatment of varicose veins. Boston Scientific is responsible for the drug's development program.
Polidocanol Endovenous Microfoam is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 study has been completed, with a total of 21 participants enrolled in the clinical trial.
Polidocanol Endovenous Microfoam has one completed clinical trial, identified as NCT01428076. This Phase 1 study was a pharmacokinetic trial of the drug in patients with varicose veins. The trial enrolled 21 participants in the United States and was a controlled, randomized study.
Polidocanol Endovenous Microfoam is a specific formulation of polidocanol, delivered as a microfoam for endovenous use. The drug is being studied for varicose veins, and the clinical trial NCT01428076 evaluates this particular microfoam formulation. The drug name reflects its unique delivery method.